News - Enhancement of Virtual HouseCall System
WAYNE, Pa., Nov. 11 /PRNewswire/ -- Covalent Group, Inc. (NASDAQ:CVGR) announced today the release of its proprietary TeleTrial System, a major enhancement to its interactive speech recognition platform, Virtual HouseCall.
TeleTrial, for use in clinical trial studies, allows for the seamless management of four key clinical trial components, namely study site administration, patient enrollment and randomization, clinical and drug supply management and collection of subjective data including patient questionnaires, diaries and surveys.
The TeleTrial suite of applications is being marketed as an extension to Covalent's clinical trial services and broadens the Company's capability to conduct larger and longer clinical trials.
It is specifically designed to improve patient recruitment and retention, assist in patient based data collection, increase study site efficiency, and decrease client costs for study medications and clinical supplies by improved inventory management.
This announcement follows the successful completion of the Company's pilot clinical study involving over 1,300 patients at 36 study sites. Virtual HouseCall continues to be marketed in the health management area where a study is currently being conducted.
Covalent provides drug development and health management solutions to pharmaceutical and device manufacturers, as well as managed care organizations. To aid its pharmaceutical and managed care customers, Covalent has developed a disease assessment system, Virtual HouseCall, and a clinical trial management system, TeleTrial, using interactive speech recognition technology.
This press release contains forward-looking statements......
Contact the Company on-line: cracorp.com |
